Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Since the discovery that activating mutations of the Ras GTPase were associated with 30% or more of human cancers, the RAF/MEK/ERK pathway has been the focus of intense drug discovery effort. Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise.
Thompson
Neil
N
Astex Technology Ltd, 436 Cambridge Science Park, Milton Rd, Cambridge CB4 0QA, UK.
Lyons
John
J
D000818:Animals; D001549:Benzamides / Q000737:chemistry / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000737:chemistry / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004159:Diphenylamine / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011725:Pyridines / Q000737:chemistry / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D000077157:Sorafenib
D001549:Benzamides; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; C506614:mirdametinib; D004159:Diphenylamine; D000077157:Sorafenib; D019908:Proto-Oncogene Proteins c-raf; D048049:Extracellular Signal-Regulated MAP Kinases